MedTrace Logo

A Study To Assess The Efficacy and Safety of HH-120 Nasal Spray for the Treatment of Mild COVID-19

NCT05713318 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2024-10-10

No results posted yet for this study

Summary

This is a randomized, double-blind, placebo-controlled Phase 2 study in participants over the age of 18 years with mild COVID-19. The main purpose of this study is to evaluate the effect on viral load clearance and clinical recovery, and safety of HH-120 nasal spray in participants over the age of 18 years with mild COVID-19 (according to the FDA definition, 2021).

Conditions

Interventions

DRUG

HH-120 nasal spray

Nasal spray daily doses of HH-120 4 times added on SOC for 6 consecutive days.

DRUG

HH-120 nasal spray

Nasal spray daily doses of HH-120 8 times added on SOC for 6 consecutive days.

DRUG

Placebo Comparator

Nasal spray daily doses of placebo 4 times added on SOC for 6 consecutive days.

DRUG

Placebo Comparator

Nasal spray daily doses of placebo 8 times added on SOC for 6 consecutive days.

Sponsors & Collaborators

  • Huahui Health

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-01-18
Primary Completion
2023-06-19
Completion
2023-06-19

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05713318 on ClinicalTrials.gov